Holen Sie sich die Stockscreener-App
2.22
0.45%
-0.010
Handel nachbörslich:
2.22
Schlusskurs vom Vortag:
$2.23
Offen:
$2.21
24-Stunden-Volumen:
393.94K
Relative Volume:
0.35
Marktkapitalisierung:
$327.16M
Einnahmen:
$72,500
Nettoeinkommen (Verlust:
$-45.96M
KGV:
-3.258
EPS:
-0.6814
Netto-Cashflow:
$-44.56M
1W Leistung:
-0.45%
1M Leistung:
+24.72%
6M Leistung:
+142.52%
1J Leistung:
+41.40%
1-Tages-Spanne:
$2.16
$2.3767
1-Wochen-Bereich:
$2.09
$2.3767
52-Wochen-Spanne:
$0.7984
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
2.22 | 297.68M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx Nv Aktie (IFRX) Neueste Nachrichten
Farallon Capital Management Acquires New Position in InflaRx NV (IFRX) - GuruFocus
InflaRx (IFRX) Latest: Ends Down by 4.72% at $2.02 in the Latest Reading; Next Test: Price Remains Between $1.92 Support and $2.12 ResistanceLarge Cap Trends - vinanet.vn
InflaRx Announces Participation in September Investor Conferences - GlobeNewswire
Commodore Capital reports 5%+ stake in InflaRx (IFRX) - Stock Titan
IFRX Q2 2026 Earnings: Wider-than-Expected Loss Raises Stakes for Clinical ExecutionMargin Guidance - Vinanet
InflaRx (IFRX) investors report 15.6% and 12.5% stakes in updated 13G/A - Stock Titan
Sirenia Capital (IFRX) discloses 8.9M InflaRx shares, a 6.1% ownership stake - Stock Titan
InflaRx (IFRX): Farallon group reports 3.33M-share, 2.3% beneficial stake - Stock Titan
EDGAR Filing Documents for 0001140361-26-033149 - SEC.gov
InflaRx N.V. SEC Filing (Aug 13, 2026) - Stock Titan
Here's Why We're Not At All Concerned With InflaRx's (NASDAQ:IFRX) Cash Burn Situation - Sahm
IFRX Q2 2026 Earnings: EPS Misses by 51.26% Yet Shares Advance 6.52%Earnings Sentiment Score - vinanet.vn
HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - marketbeat.com
Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00 - MarketBeat
InflaRx N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC and Abigail Johnson (IFRX) disclose 5.5% Inflarx stake in Schedule 13G - Stock Titan
InflaRx NV reports results for the quarter ended June 30Earnings Summary - TradingView
InflaRx N.V. (IFRX) sets up $250M shelf for stock, debt and warrants - Stock Titan
IFRX: Advanced pipeline in AAV and renal diseases, with strong funding and reduced net loss - TradingView
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K - TipRanks
InflaRx Q2 2026 earnings: Lower costs narrow the operating loss - TradingKey
InflaRx (Nasdaq: IFRX) raises $140m, funds C5a pipeline into 2029 - Stock Titan
InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases - Quiver Quantitative
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones - Yahoo! Finance Canada
IFRX Q2'26 Earnings: EPS estimate is (0.07) USD - TradingView
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
InflaRx NV expected to post a loss of 6 cents a shareEarnings Preview - TradingView
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - sharewise.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline FocusNext Quarter Guidance - vinanet.vn
InflaRx N.V. Revenue Breakdown – NASDAQ:IFRX - TradingView
No Conference Call Planned for InflaRx's Aug. 6 Results - stocktitan.net
IFRX Q2'26 Earnings: revenue estimate is 6.40K USD - TradingView
InflaRx (NASDAQ:IFRX) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx (NASDAQ:IFRX) Trading Down 2.3%Time to Sell? - MarketBeat
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx N.V. Revenue Breakdown – SWB:IF0 - TradingView
InflaRx NV (IFRX) Institutional Confidence - TradingKey
IFRX|InflaRx NV|Price:1.740|Chg%:+0.010 - TradingKey
IFRX|InflaRx NV|Price:1.690|Chg%:-0.050 - TradingKey
InflaRx N.V. (IFRX) Q1 2026 Earnings: Narrower Loss Beats Expectations, No Revenue Reported - vinanet.vn
TradingKey - TradingKey
InflaRx N.V. Revenue Breakdown – BOATS:IFRX - TradingView
InflaRx NV (IFRX) Cash Flow - TradingKey
InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IFRX Q1 2026 Earnings: Beats EPS Estimates Despite No Revenue, Pipeline Progress Drives Stock Up 1.92%Buyback Announcement Report - vinanet.vn
IFRX Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Pipeline AdvancesEarnings Revision Report - vinanet.vn
InflaRx (IFRX) Under Pressure as Shares Slip 2.88% Toward Key SupportAlgorithmic Stock Picks - dars.gov.et
Finanzdaten der Inflarx Nv-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):